top of page
Image-empty-state.png

Evelina Tacconelli

Director

Email:

Phone:

+39 045 812 8243

Short biography

Evelina Tacconelli is a Full Professor of Infectious Diseases at the University of Verona, Italy and Head of the DZIF Clinical Research Unit on healthcare associated infections and antimicrobial resistance at the Tübingen University, Germany. She has been Lecturer on Medicine at the Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA. She was recipient of award from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) for research excellence. Consultant for WHO, ECDC and EMA on antimicrobial resistance and infection control. Her main areas of scientific interest are epidemiology, clinical and therapeutic aspects of healthcare-associated infections and preventive measures aimed to reduce the spreading of antibiotic-resistant bacteria. Co-coordinator of the Unit of research on healthcare-associated and antibiotic-resistant bacterial infections (TTU-HAARBI) within the German Center for Infectious Diseases (DZIF). She is the ESCMID Guideline Officer for Infectious Diseases and Clinical Microbiology. Member of the SAB of the JPI-AMR. Chair of the 2018 WHO Priority List of Pathogens for R&D of new antibiotics. Chair of the European Committee of Infection Control (EUCIC). Chair of the ESCMID guidelines on prevention and therapy of infections due to multidrug-resistant Gram negative bacteria (MDR-GN) and EUCIC guideline on decolonization procedures for patients colonized with MDR-GN. Involved (partner site or coordinator) in many European studies on prevention and therapy of infections caused by antibiotic-resistant bacteria financed by European Commission, WHO, JPI-AMR, Horizon2020, DG-Sanco, IMI, and DZIF. She serves on the International Advisory Board of Lancet Infectious Diseases, Editorial Board of Journal of Antimicrobial Chemotherapy and Scientific Committee of Clinical Microbiology and Infection. Author and co-author of more than 200 papers listed in SCI-JCR and NIH Medline.

Projects

VACCELERATE

AMR Travel Tool

GAP-ON€-2

ENACT-SOS COVID

COMBACTE-NET-EXPECT

MPX-RESPONSE

PRIMAVERA

ORCHESTRA

VALUE-DX

ENACT-REACT COVID (microbiome signatures)

Chemsex MSM

COHERENCE

WHO BPPL

Sentinella

Excellence Centres

ENACT-REACT COVID (long term follow up)

ARCH-NET

ECRAID-Base

EU-RESPONSE

SOLIDARITY-Italy

ENACT-REACT COVID (risk assessment)

Publications

4/9/23

*

The Lancet Infectious Diseases

How to tailor recommendations on the treatment of multi-drug resistant Gram-negative infections at country level integrating antibiotic stewardship principles within the GRADE-ADOLOPMENT framework

21/7/23

eClinicalMedicine

Clinical phenotypes and quality of life to define post-COVID-19 syndrome: a cluster analysis of the multinational, prospective ORCHESTRA cohort

14/8/23

Vaccines

How European Research Projects Can Support Vaccination Strategies: The Case of the ORCHESTRA Project for SARS-CoV-2

21/7/23

*

eClinical Medicine

Clinical phenotypes and quality of life to define post-COVID-19 syndrome: a cluster analysis of the multinational, prospective ORCHESTRA cohort

1/8/23

Journal of Antimicrobial Chemotherapy

Association of ward-level antibiotic consumption with healthcare-associated Clostridioides difficile infections: an ecological study in five German university hospitals, 2017–2019

14/7/23

*

The Lancet Regional Health – Europe

Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study

bottom of page